Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia

PALO ALTO, Calif.--(BUSINESS WIRE)-- #AML--Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial of IO-202, a first-in-class antibody against LILRB4 (ILT3), in AML and CMML

Click to view original post